Vimarsana
Biggest News Aggregation in the World

Page 42 - Aptar Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Aptar Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Aptar Pharma Today - Breaking & Trending Today

Aptar Pharma and RDD Online Partner to Present Reimagined RDD 2021 Virtual Conference, Live Events May 4-7, 2021 - Vimarsana News

Aptar Pharma and RDD Online Partner to Present Reimagined RDD 2021 Virtual Conference, Live Events May 4-7, 2021

·     ·     ·     ·       From the Knowledge Spaces, delegates will have the opportunity to connect in real-time during Explore with Experts moderated discussions between 4:00–6:15PM CET on each day of live RDD 2021 events. RDD Messaging and Meeting scheduling will allow experts and delegates to interact both during and after the conference.   RDD 2021 will include the widely sought-after Workshop Presentations, which enable delegates to discover new solutions, explore opportunities and enter into dialogue directly with the workshop presenters. This year, Conve...

Merck Helps Produce J&J's COVID-19 Vaccine and More News - Vimarsana News

Merck Helps Produce J&J's COVID-19 Vaccine and More News

YouTube Demand for the COVID-19 vaccines severely exceeds current supply. So, in a move similar to the unprecedented collaboration between Sanofi and Pfizer, now Merck has stepped up to help get the Johnson & Johnson vaccine to the market quicker. Top headlines in the community of pharmaceutical packaging keep you up to date on what’s happening now.   Merck Helps Produce J&J’s COVID-19 Vaccine Demand for the COVID-19 vaccines severely exceeds current supply. So, in a move similar to the unprecedented collaboration between Sanofi and Pfizer, now Merck has stepped...

Worldwide Sterile Small Molecule Fill/Finish Services Industry to 2030 - Featuring Pfizer CentreOne, Delpharm & Rompharm Among Others - Vimarsana News

Worldwide Sterile Small Molecule Fill/Finish Services Industry to 2030 - Featuring Pfizer CentreOne, Delpharm & Rompharm Among Others

Share this article Share this article ResearchAndMarkets.com's offering. This report features an extensive study of the current market landscape and the future potential of sterile fill/finish services for small molecule drugs. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In fact, in 2019, the FDA's Center for Drug Evaluation and Research approved 48 small molecule drugs, representing 70% of the new molecular entities (NMEs) clearing regulat...

Noble Launches Human Factors Engineering Services to Support Product Development and FDA Approval of Med Devices and Combination Products - Vimarsana News

Noble Launches Human Factors Engineering Services to Support Product Development and FDA Approval of Med Devices and Combination Products

Noble Launches Human Factors Engineering Services to Support Product Development and FDA Approval of Med Devices and Combination Products Human Factors Plus (HF+) is an extension of the company's understanding of the patient experience when it comes to self-administering drug therapies. This content was submitted directly to this website by the supplier. Feb 3rd, 2021 Noble, an Aptar Pharma company and provider of drug delivery training device programs for pharmaceutical companies and original equipment manufacturers, announced the launch of Human Factors Plus (HF+), an expanded service to fu...

Twenty Q4 deals round out a record-setting 2020 for digital health M&A - Vimarsana News

Twenty Q4 deals round out a record-setting 2020 for digital health M&A

Share Back in July, we theorized that 2020 could end up being a record-setting year for digital health M&A, and that’s turned out to be the case. With 35 deals in the first half of the year, nine in the third quarter, and 20 more in Q4, MobiHealthNews and its sister publications tracked a staggering 64 deals this year. That count, by the way, excludes “blank check” or Special Purpose Acquisition Company deals, which are technically acquisitions but often function more like IPOs. SPAC deals have been popular this year, with MobiHealthNews tracking at least six. Our usual caveats ap...